However, our results are consistent with clinical findings that showed poorer response rates of PD-1/PD-L1 targeting agents in lung cancer patients with EGFR mutations, and may explain at least part of the reasons for the lower efficacy of these agents in these specific patients. This evidence concerns the gene EGFR and lung carcinoma.